Pathophysiology, Diagnosis, Treatment and Emerging Neurotherapeutic Targets for Progressive Multiple Sclerosis

How patients with multiple sclerosis acquire disability

(2022) Fred D. Lublin et al.   BRAIN

Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis

(2022) Thomas E. Williams et al.   Neurology-Neuroimmunology & Neuroinflammation

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis

(2022) Patrick Vermersch et al.   Neurology-Neuroimmunology & Neuroinflammation

Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation

(2022) Arie R. Gafson et al.   JAMA Network Open

Updates and advances in multiple sclerosis neurotherapeutics

(2022) Moein Amin et al.   Neurodegenerative Disease Management

Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype

(2021) Andrew D. Goodman et al.   Annals of Clinical and Translational Neurology

Diagnosis and Treatment of Multiple Sclerosis

(2021) Marisa P. McGinley et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis

(2021) Robert J Fox et al.   Multiple Sclerosis Journal

Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance

(2021) Kathleen M Zackowski et al.   Multiple Sclerosis Journal

Early predictors of conversion to secondary progressive multiple sclerosis

(2021) Mahdi Barzegar et al.   Multiple Sclerosis and Related Disorders

Hydroxychloroquine for Primary Progressive Multiple Sclerosis

(2021) Marcus W. Koch et al.   ANNALS OF NEUROLOGY

Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal

(2021) Alan J Thompson et al.   Multiple Sclerosis Journal

Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis

(2021) Heather Y. F. Yong et al.   Nature Reviews Neurology

The 2013 clinical course descriptors for multiple sclerosis

(2020) Fred D. Lublin et al.   NEUROLOGY

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Bruce A C Cree et al.   LANCET NEUROLOGY

Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study

(2020) M Blinkenberg et al.   Multiple Sclerosis and Related Disorders

Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study

(2020) Robert T. Naismith et al.   NEUROLOGY

Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective

(2020) Massimo Filippi et al.   JAMA Neurology

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

(2019) Diego Cadavid et al.   LANCET NEUROLOGY

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

(2018) Raju Kapoor et al.   LANCET NEUROLOGY

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

(2018) Jerry S. Wolinsky et al.   ANNALS OF NEUROLOGY

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

(2018) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial

(2018) Edward J Fox et al.   Multiple Sclerosis Journal

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

(2017) Daniel Ontaneda et al.   LANCET

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis

(2017) Peter Feys et al.   Multiple Sclerosis Journal

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

(2017) Robert W Motl et al.   Multiple Sclerosis Journal

Targets of therapy in progressive MS

(2017) Hans Lassmann   Multiple Sclerosis Journal

Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis

(2017) Laura J Balcer et al.   Multiple Sclerosis Journal

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis

(2017) Ralph HB Benedict et al.   Multiple Sclerosis Journal

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis

(2017) Peter Feys et al.   Multiple Sclerosis Journal

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

(2017) Robert W Motl et al.   Multiple Sclerosis Journal

Targets of therapy in progressive MS

(2017) Hans Lassmann   Multiple Sclerosis Journal

Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis

(2017) Laura J Balcer et al.   Multiple Sclerosis Journal

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis

(2017) Ralph HB Benedict et al.   Multiple Sclerosis Journal

Defining secondary progressive multiple sclerosis

(2016) Johannes Lorscheider et al.   BRAIN

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

Treatment of progressive multiple sclerosis: what works, what does not, and what is needed

(2015) Anthony Feinstein et al.   LANCET NEUROLOGY

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis

(2014) Sandra Meyer-Moock et al.   BMC Neurology

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

(2014) Jeremy Chataway et al.   LANCET

Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis

(2014) Ilana Katz Sand et al.   Multiple Sclerosis Journal

Neuro-QOL: Brief measures of health-related quality of life for clinical research in neurology

(2012) D. Cella et al.   NEUROLOGY

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008

(2010) David Cella et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY